Milestone Scientific Expands Board with Dr. Sayed for Growth
Milestone Scientific Welcomes Dr. Dawood Sayed to Its Board
Milestone Scientific Inc. (NYSE: MLSS), located in Roseland, New Jersey, is setting exciting new directions for its future by welcoming Dr. Dawood Sayed, a renowned expert in interventional pain medicine, to its Board of Directors. This strategic appointment enhances the company’s efforts in revolutionizing pain management through innovative technology.
Dr. Sayed's Remarkable Credentials
Dr. Sayed, who is affiliated with the University of Kansas Medical Center, holds prestigious roles including Professor of Anesthesiology and Pain Medicine and Division Chief of Pain Medicine. His impressive resume includes directing Interventional Spine Services and the Center for Neuromodulation, where he expands the frontiers of pain therapy. Throughout his career, Dr. Sayed has made significant contributions to the field, emphasizing minimally invasive therapy and health system innovations.
Leadership in Pain Medicine
As a Vice Chairman and Co-Founder of the American Society of Pain and Neuroscience (ASPN), Dr. Sayed actively collaborates with key players in healthcare to promote access to cutting-edge pain relief technologies. His dedication has resulted in multiple accolades, including a recent prestigious award from the North American Neuromodulation Society (NANS).
Enhancing Milestone's Strategic Vision
“Welcoming Dr. Sayed to the board is a pivotal moment for Milestone Scientific,” said Neal Goldman, Chairman of the company. “His extensive expertise will be vital as we continue to introduce our CompuFlo® technology into the pain management and spinal intervention sectors. This aligns with our objective to incorporate leading medical professionals into our strategic vision.”
Commitment to Innovation
The CompuFlo® Epidural System stands as a breakthrough technology that elevates the precision of epidural space identification with real-time pressure feedback. It offers a marked advancement over traditional methods, promoting safer procedures and improved patient outcomes. The growing recognition from clinical leaders and the establishment of a Medicare Part B payment rate under CPT® code 0777T demonstrate an increasing acceptance among healthcare professionals and insurers.
Leadership's Perspective on Growth
Eric Hines, the Chief Executive Officer of Milestone Scientific, commented on Dr. Sayed's addition to the board, stating, “This is a key advancement in our vision to establish a market-oriented company informed by clinical realities. Dr. Sayed’s deep understanding of healthcare systems and reimbursement strategies will be crucial as we increase our market foothold in interventional pain management.”
Dr. Sayed's Vision for the Future
Expressing his enthusiasm about joining Milestone Scientific, Dr. Sayed stated, “At this critical juncture for interventional pain care, the emphasis on innovation is paramount for enhancing patient outcomes and reducing dependency on opioids. I am excited to contribute to the advancement of CompuFlo®.”
Contributions to Medical Literature
With over 100 peer-reviewed publications, Dr. Sayed plays a significant role in shaping national guidelines for pain medicine. His participation in clinical trials focusing on neuromodulation and spinal treatment reflects his commitment to advancing therapeutic practices. He also acts as a medical advisor to leading medical technology firms, contributing to the evolution of treatment methodologies.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) specializes in medical research and development with a focus on pioneering injection technologies. Their innovative systems aim to empower precise and comfortable injection experiences in medical and dental applications. By harnessing their proprietary Dynamic Pressure Sensing Technology, they are reshaping the standards for drug delivery systems.
For more insights about Milestone Scientific, you can view their brand video or get details on their ongoing projects by visiting their official website.
Frequently Asked Questions
Who is Dr. Dawood Sayed?
Dr. Dawood Sayed is a prominent pain medicine expert and a new member of the Milestone Scientific Board of Directors.
What role does CompuFlo® play in pain management?
CompuFlo® Epidural System enhances the safety and efficacy of epidural procedures by providing real-time pressure feedback.
What is Milestone Scientific's mission?
Milestone Scientific focuses on innovating injection technologies that improve patient comfort and outcomes.
How has Dr. Sayed impacted the field of pain management?
Dr. Sayed has significantly influenced pain management through research, guidelines, and innovative treatment practices.
What distinguishes Milestone Scientific's technology?
Milestone's technology utilizes advanced sensing systems to ensure precise delivery and monitoring of injections, setting it apart in the healthcare field.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
